Histogen Inc has a consensus price target of $2.75, established from looking at the 3 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and Canaccord Genuity on March 29, 2022, August 30, 2021, and June 4, 2021. With an average price target of $2.63 between HC Wainwright & Co., HC Wainwright & Co., and Canaccord Genuity, there's an implied 650.24% upside for Histogen Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/29/2022 | HSTO | Buy Now | Histogen | $0.35 | 327.35% | HC Wainwright & Co. | Douglas Tsao | $48 → $30 | Maintains | Buy | Get Alert |
08/30/2021 | HSTO | Buy Now | Histogen | $0.35 | 583.76% | HC Wainwright & Co. | Douglas Tsao | — | Initiates | → Buy | Get Alert |
06/04/2021 | HSTO | Buy Now | Histogen | $0.35 | 1039.6% | Canaccord Genuity | — | — | Maintains | Buy | Get Alert |
The latest price target for Histogen (OTCEM: HSTO) was reported by HC Wainwright & Co. on March 29, 2022. The analyst firm set a price target for $1.50 expecting HSTO to rise to within 12 months (a possible 327.35% upside). 0 analyst firms have reported ratings in the last year.
The latest analyst rating for Histogen (OTCEM: HSTO) was provided by HC Wainwright & Co., and Histogen maintained their buy rating.
There is no last upgrade for Histogen.
There is no last downgrade for Histogen.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Histogen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Histogen was filed on March 29, 2022 so you should expect the next rating to be made available sometime around March 29, 2023.
While ratings are subjective and will change, the latest Histogen (HSTO) rating was a maintained with a price target of $2.40 to $1.50. The current price Histogen (HSTO) is trading at is $0.35, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.